Oxidative stress and psoriasis: The effect of antitumour necrosis factor-α inhibitor treatment

British Journal of Dermatology

Volumn 168, Issue 5, 2013, Pages 984-989

  Bacchetti, T ^a   Campanati, A ^a   Ferretti, G ^a   Simonetti, O ^a   Liberati, G ^a   Offidani, A M ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; PSORIASIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LIPID PEROXIDATION; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876980690     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12144     Document Type: Article

References (43)

1. Orciani M, Campanati A, Salvolini E, et al. The mesenchymal stem cell profile in psoriasis. Br J Dermatol 2011; 165: 585-92.
2. Vizzardi E, Raddino R, Teli M, et al. Psoriasis and cardiovascular diseases. Acta Cardiol 2010; 65: 337-40.
3. Gelfand JM, Azfar RS, Mehta NN,. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 2010; 130: 919-22.
4. Ferretti G, Bacchetti T, Campanati A, et al. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol 2012; 166: 204-7.
5. Vanizor Kural B, Orem A, Cimşit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82.
6. Tekin NS, Tekin IO, Barut F, Sipahi EY,. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007; 2007: 78454.
7. Kokcam I, Naziroglu M,. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta 1999; 289: 23-31.
8. Bos JD, de Rie MA,. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-6.
9. Hotamisligil GS,. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
10. Griffiths CE,. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol 2003; 17 (Suppl. 2): 1-5.
11. Simonetti O, Ferretti G, Salvi A, et al. Plasma lipid changes in psoriatic children. Dermatology 1992; 185: 96-100.
12. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC,. Lipid disturbances in psoriasis: an update. Mediators Inflamm 2010; 2010: 535612.
13. Ferretti G, Alleva R, Taus M, Simonetti O, Cinti B, Offidani AM, Bossi G, Curatola G,. Abnormalities of plasma lipoprotein composition and fluidity in psoriasis. Acta Derm Venereol 1994; 74: 171-5.
14. Offidani AM, Ferretti G, Taus M, Simonetti O, Dousset N, Valdiguie P, Curatola G, Bossi G,. Lipoprotein peroxidation in adult psoriatic patients. Acta Derm Venereol Suppl (Stockh) 1994; 186: 38-40.
15. Negre-Salvayre A, Dousset N, Ferretti G, et al. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006; 41: 1031-40.
16. G HB, Rao VS, Kakkar VV,. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol 2011; 2011: 274629.
17. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-30.
18. Campanati A, Orciani M, Gorbi S, et al. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis. Br J Dermatol 2012; 167: 68-76.
19. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731-6.
20. van Eijk IC, de Vries MK, Levels JHM, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1324-30.
21. Feldman SR, Krueger GG,. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2): 65-8, discussion 69-73.
22. Ferretti G, Bacchetti T, Masciangelo S, et al. Lipid peroxidation in stroke patients. Clin Chem Lab Med 2008; 46: 113-17.
23. Kontush A, Beisiegel U,. Measurement of oxidizability of blood plasma. Methods Enzymol 1999; 299: 35-49.
24. Ou B, Hampsch-Woodill M, Prior RL,. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J Agric Food Chem 2001; 49: 4619-26.
25. Rock W, Rosenblat M, Miller-Lotan R, et al. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem 2008; 56: 8704-13.
26. Lestre S, Diamantino F, Veloso L, et al. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol 2011; 21: 916-20.
27. Jiménez-Puya R, Gõmez-Garcia F, Amorrich-Campos V, Moreno-Giménez JC,. Etanercept: efficacy and safety. J Eur Acad Dermatol Venereol 2009; 23: 402-5.
28. Reich K, Burden AD, Eaton JN, Hawkins NS,. Efficacy of biologics in the treatment of moderate-to-severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-88.
29. Kageyama Y, Takahashi M, Nagafusa T, et al. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 2008; 28: 245-51.
30. Gutierrez M, De Angelis R, Bernardini ML, Filippucci E, Goteri G, Brandozzi G, Lemme G, Campanati A, Grassi W, Offidani A,. Clinical, power Doppler sonography and histological assessment of the psoriatic plaque: short-term monitoring in patients treated with etanercept. Br J Dermatol 2011; 164: 33-7.
31. Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Stramazzotti D, Morichetti D, Bernardini ML, Mannello B, Fabris G, Offidani A,. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol 2007; 157: 1155-60.
32. Karkucak M, Capkin E, Alver A, et al. The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. Clin Rheumatol 2010; 29: 303-7.
33. Túnez I, Feijõo M, Huerta G, et al. The effect of infliximab on oxidative stress in chronic inflammatory joint disease. Curr Med Res Opin 2007; 23: 1259-67.
34. Woo CH, Kim TH, Choi JA, et al. Inhibition of receptor internalization attenuates the TNFα-induced ROS generation in non-phagocytic cells. Biochem Biophys Res Commun 2006; 351: 972-8.
35. Miesel R, Murphy MP, Kroger H,. Enhanced mitochondrial radical production in patients with rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 1996; 25: 161-9.
36. Sakon S, Xue X, Takekawa M, et al. NF-κB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 2003; 22: 3898-909.
37. Mur E, Zabernigg A, Hilbe W, et al. Oxidative burst of neutrophils in patients with rheumatoid arthritis: influence of various cytokines and medication. Clin Exp Rheumatol 1997; 15: 233-7.
38. Lamont J, Campbell J, FitzGerald P,. Measurement of individual versus total antioxidants. Clin Chem 1997; 43: 852-4.
39. Kannampuzha J, Darling PB, Maguire GF, et al. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis. Clin Nephrol 2010; 73: 131-8.
40. Manfredini V, Biancini GB, Vanzin CS, et al. Apolipoprotein, C-reactive protein and oxidative stress parameters in dyslipidemic type 2 diabetic patients treated or not with simvastatin. Arch Med Res 2010; 41: 104-9.
41. Mackness B, Hine D, McElduff P, Mackness M,. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 2006; 186: 396-401.
42. Ferretti G, Bacchetti T, Masciangelo S, et al. Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome. Dis Model Mech 2012; 5: 698-705.
43. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53.